TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02447497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Surgical Skin Preparation - Abdominal Region
Description: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline - Abdominal Region
Description: 0.9% sodium chloride applied with foam applicator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Surgical Skin Preparation - Inguinal Region
Description: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline - Inguinal Region
Description: 0.9% sodium chloride applied with foam applicator
Study: NCT02872649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Study: NCT00991757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carisbamate
Description: Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
Study: NCT00515359

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Propofol Sedation
Description: Intermittent versus continuous dosage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Propofol Sedation
Description: intermittent vs continuous dosage
Study: NCT01342250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus low dose hUC-MSCs treatment
Description: patients will receive the conventional therapy plus low dose hUC-MSCs treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus medium dose hUC-MSCs treatment
Description: patients will receive conventional therapy plus medium dose hUC-MSCs treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus high dose hUC-MSCs treatment
Description: patients will receive conventional therapy plus high dose hUC-MSCs treatment
Study: NCT03147131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
Study: NCT03398512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exploratory laparoscopy or laparotomy
Description: Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
Study: NCT02520882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-Aca-BBN
Description: 68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study: NCT00189306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
Study: NCT02326077

Intervention type: OTHER
Intervention: Ultrasound
Description: Monitoring of the mechanism of labor

Intervention type: OTHER
Intervention: Acceptability of ultrasound monitoring of labor
Description: Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor

Intervention type: OTHER
Intervention: Patients' experience regarding intrapartum ultrasound
Description: The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
Study: NCT02296580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nativis Voyager RFE Therapy
Description: Nativis Voyager Radiofrequency Energy Therapy
Study: NCT02172248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT01508026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan 1
Description: Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan 2
Description: Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan 3
Description: Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol 1
Description: Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol 2
Description: Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 1
Description: Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 2
Description: Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo, oral administration
Study: NCT02779309

Intervention type: PROCEDURE
Intervention: Home Care/RAI-HC Assessment
Description: Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).

Intervention type: PROCEDURE
Intervention: Home Care/RAI-HC Assessment
Description: Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
Study: NCT01776281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study: NCT00645489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members

Intervention type: OTHER
Group type: OTHER
Intervention: wait list
Description: Wait list
Study: NCT00212095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and ketoconazole
Description: Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration.
Study: NCT01026961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine HCL
Description: Phenylephrine HCL 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
Description: Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
Study: NCT04943809

Intervention type: DEVICE
Intervention: POD 26P AY FT
Description: Routine cataract surgery
Study: NCT01857830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Retreat
Description: The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
Study: NCT01734915

Intervention type: DEVICE
Intervention: Circulating tumor cell chip
Description: three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
Study: NCT03499457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: chalange test of 50 mg, and after an hour 500 mg
Study: NCT03451916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
Study: NCT00550134

Intervention type: BEHAVIORAL
Intervention: Questionnaires, MRI, Comet assay and Cell senescence
Description: Neuropsychological and psychological testing MRI, Comet assay and Cell senescence

Intervention type: BEHAVIORAL
Intervention: Questionnaires, MRI, Comet assay and Cell senescence
Description: Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
Study: NCT01857830

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Relaxation Group
Description: Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
Study: NCT06374537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Therapy
Description: Participants will attend 2 muscle therapy sessions a week for 12 months, for one hour each.
Study: NCT05047562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Group
Description: 16 Pilates exercise sessions twice a week for 2 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Segmental Stabilization group
Description: 16 sessions of segmental stabilization exercises, 2 times a week for 2 months.
Study: NCT00566943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSD Veritas Collagen Matrix
Description: Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric by-pass surgery with no buttress
Description: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
Study: NCT01925261

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00550134

Intervention type: BEHAVIORAL
Intervention: Questionnaires, MRI, Comet assay and Cell senescence
Description: Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
Study: NCT01778738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy
Description: Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy
Description: Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrecomy
Description: Vertical sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bastric bypass
Description: Gastric bypass surgery
Study: NCT02010658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Aid
Study: NCT04865549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNB + TAD + Lymphadenectomy
Description: Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
Study: NCT00138073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-based waveform interpretation guide
Description: Use of an educational website.
Study: NCT01192529

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supressi. T-Diet plus Range
Description: Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Protein. T-Diet plus Range
Description: T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
Study: NCT02090621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis
Description: Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
Study: NCT03320850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA and Hydrogel admixture
Description: BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA and Hydrogel admixture
Description: BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA and Hydrogel admixture
Description: BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA and Hydrogel admixture
Description: BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Hydrogel admixture
Description: Placebo and Hydrogel admixture administered as a single intravesical instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Hydrogel admixture
Description: Placebo and Hydrogel admixture administered as a single intravesical instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Hydrogel admixture
Description: Placebo and Hydrogel admixture administered as a single intravesical instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Hydrogel admixture
Description: Placebo and Hydrogel admixture administered as a single intravesical instillation
Study: NCT02580669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A neuropsychological assessment is done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A neuropsychological assessment is done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A neuropsychological assessment is done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic consultation
Description: A neurologic consultation is done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic consultation
Description: A neurologic consultation is done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs (with vasoreactivity testing)
Description: MRIs (with vasoreactivity testing) is done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs (with vasoreactivity testing)
Description: MRIs (with vasoreactivity testing) is done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs (with vasoreactivity testing)
Description: MRIs (with vasoreactivity testing) is done
Study: NCT02464761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visudyne
Study: NCT01664949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose Based Eye Drop Formulation A
Description: Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
Description: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
Study: NCT03195647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study: NCT02170896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS tartaric acid solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS tartaric acid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Study: NCT04178642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment
Description: Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous destruction of the tumor
Description: Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
Study: NCT03250481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Sedation targeted to RASS -3-0 or RI 20-40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sedation targeted to RASS -3-0 or RI 20-40